These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Author: Jennings PE, Belch JJ.
    Journal: Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442.
    Abstract:
    In long-term clinical studies the beneficial effects of gliclazide on platelets have been related to a reduction in oxidative stress. This property is because of gliclazide's free radical scavenging ability that relates to the unique amino azabicyclo-octane ring, which is grafted on to the sulfonylurea. During a blinded clinical trial, the possible effects of gliclazide were assessed in 30 non-insulin-dependent diabetic patients. All patients had been treated for diabetes for more than 2 years (mean 8 years) and had been established on glibenclamide for over 2 years with or without adjunctive metformin therapy. Patients were studied for 6 months and randomized to continue either their present dose of glibenclamide or to be converted to an equipotent dose of gliclazide. Measurements were taken of hemostatic variables, the oxidative status of the plasma, and the redox status, both extracellularly as plasma albuminthiols (PSH) and lipid peroxides, and intracellularly as red blood cell superoxide dismutase activity (SOD). At 3 months, diabetic control was unaltered, but there were significant improvements in the oxidative status of the gliclazide-treated patients. Lipid peroxides decreased (8.3 +/- 1.1 to 7.0 +/- 0.06 mumol/l, P < 0.01) and red blood cell SOD increased (135 +/- 21 to 152 +/- 36 micrograms/ml, P < 0.05). PSH levels were unaltered at 453 +/- 38 mumol/l, whereas they had decreased significantly in the glibenclamide patients (414 +/- 34 mumol/l, P < 0.05), resulting in a significant difference between the 2 treatment groups (P < 0.004). Platelet reactivity to collagen also improved in the gliclazide-treated patients, decreasing from 65.1% +/- 14% to 50.8 +/- 24% (p < 0.01). The reactivity of the platelets remained unaltered in the glibenclamide patients. At 6 months, the significant differences between the 2 treatment groups remained. Hence, gliclazide was shown in a clinical study to have free radical scavenging activity independent of glycemic control.
    [Abstract] [Full Text] [Related] [New Search]